Gilead hires hepatitis C sales force, reports quarterly growth from HIV drugs
This article was originally published in Scrip
Executive Summary
Gilead Sciences is ready to launch its new hepatitis C drug sofosbuvir and already hired 150 sales specialists who will focus exclusively on the product, the company said.